Statistically significant increase in weight caused by low-dose quetiapine

Pharmacotherapy

Volumn 30, Issue 10, 2010, Pages 1011-1015

  Williams, Scott G ^a   Alinejad, Nima A ^b   Williams, Jeannie A ^a   Cruess, David F ^c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Andrews Air Force Base ^*  (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Adverse effects; Antipsychotics; Quetiapine; Weight

Indexed keywords

QUETIAPINE;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL ANALYSIS; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; RECEPTORS, HISTAMINE H1; RECEPTORS, SEROTONIN, 5-HT2; RETROSPECTIVE STUDIES; WEIGHT GAIN; YOUNG ADULT;

EID: 77957681242     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.10.1011     Document Type: Article

References (23)

1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-96.
2. Kelleher J, Centorrino F, Albert M, Baldessarini R. Advances in atypical antipsychotics for the treatment of schizophrenia. CNS Drugs 2002;16:249-61.
3. Meltzer H, McGurk S. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophren Bull 1999;25:233-55. (Pubitemid 29272503)
4. Bergman R, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005;66:504-14.
5. Allison D, Mentore J, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
6. Vestri H, Maianu L, Moellering D, Garvey W. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis and antilipolysis. Neuropsychopharmacology 2007;32:765-72.
7. 1 histamine receptor affinity predicts short term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-26.
8. Lieberman JA, Stroup TS, McEvoy JP, et al, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
9. Parsons B, Allison D, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009;110:103-10.
10. Patel NC, Kistler JS, James EB, Crismon ML. A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy 2004;24:824-30.
11. Vedantam S. Silenced drug sturs an uproar. Washington Post. March 18, 2009. Available from www.washingtonpost.com/wpdyn/content/article/2009/3/17/ AR2009031703786.html. Accessed April 15, 2009.
12. Brecher M, Leong RW, Stening G, et al. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry 2007;68:597-603. (Pubitemid 46663043)
13. Bushe C, Sniadecki J, Bradley A, Poole Hoffmann V. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. J Psychopharmacol 2010;24:1001-9.
14. McEvoy J, Lieberman J, Perkins D, et al. Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1050-60. (Pubitemid 47121394)
15. Anderson IM, Sarsfield A, Haddad PM. Efficacy, safety and tolerability of quetiapine augmentation in treatment-resistant depression: an open-label, pilot study. J Affect Disord 2009;117:116-19.
16. Adler CM, Fleck DE, Brecher M, Strakowski SM. Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder. J Affect Disord 2007;100(suppl 1):S15-22. (Pubitemid 46818454)
17. Hartung D, Wisdom J, Pollack D, et al. Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. J Clin Psychiatry 2008;69:1540-7.
18. Philip NS, Mello K, Carpenter LL, et al. Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Ann Clin Psychiatry 2008;20:15-20. (Pubitemid 351302398)
19. Centers of Disease Control and Prevention. U.S. obesity trends. Available from www.cdc.gov/obesity/data/trends.html. Accessed April 15, 2009.
20. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68(suppl 1):20-7.
21. Suppes T, McElroy SL, Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 U.S. psychiatrists. Psychopharmacol Bull 2007;40:22-37; quiz 38-40.
22. Buckley P, Miller D, Singer B, et al. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005;79:281-8.
23. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.